The inaugural Biosimilars Commercialisation Summit is the only forum to dive deep into commercial strategy on a global level.
Over 3 days of expert case-study presentations and interactive sessions this forum will enable you to tailor your commercial strategy to both established and emerging markets. Taking into consideration global regulations and healthcare systems, methods to boost stakeholder confidence and pricing, this summit will give you the tools to ensure your biosimilar survives in this fierce market.
Join us in May to:
- Exploit opportunities to broaden patient access by hearing insight from Sandoz and Gedeon Ritcher on how to break into new and emerging markets, with huge scope for economic growth
- Engage in panel discussions with Fresenius Kabi, NICE and the NHS to overcome the lack of confidence at each level, in an effort to battle misinformation and ensure a complete, end-to-end strategy
- Gain a comprehensive knowledge of global healthcare systems and regulatory affairs, giving you the tools to develop a bulletproof and international commercial strategy
- Benchmark your commercial strategy against big pharma and SMEs as they present case studies on launching biosimilars into the European market in 2019 and avoid competition
- Facilitate your commercial strategy by engaging collaboratively with the development and manufacturing functions to increase efficiency and reach your target market sooner
In the lead up to the forthcoming “Biosimilars Commercialisation Summit” happening in May 2019, Pharma IQ had the opportunity to interview industry experts:
- Jose Carlos Ferreyra, President at Mexican Pharmaceutical Institute
- Fabiola Santillan, Country Manager at TTY Biopharm
- Pankaj Chaudhari, Manager - Global Regulatory Affairs (Biosimilars) at IQVIA
They shared their thoughts on the key factors to take into account when launching in the South Asian and Latin American regions.
Download the full interviews to get insights on how to win in these markets.
We asked commercialisation experts from the biosimilars industry about how they are investing in their development, and market access strategy.
Download this piece to learn about:
- The reasons why companies aren't currently outsourcing
- The biggest factors in choosing a new solution provider
- The biggest challenges in biosimilar commercialisation currently
Ahead of the Biosimilars Commercialisation Summit Pharma IQ sat down and spoke with Kalveer Flora, Specialist Pharmacist Rheumatology and Biosimilars, London North West Healthcare NHS Trust to talk about the adoption of biosimilars in the market.
Download this piece to gain insight into:
- The importance of offering patients guidance when switching between biologics and biosimilars
- What concerns inhibit prescribers switching patients to biosimilars
- How the UK market compares to the rest of the world on stakeholder confidence and acceptance of biosimilars
The international regenerative medicines market – which includes the likes of cell therapies, gene/gene-modified cell therapy and tissue engineering – is set to climb to around $67 billion by 2020. Alongside, discovering therapies that will treat cancer and orphan diseases, many in the industry are hungry to land grab market share and produce the next blockbuster product.
Pharma IQ spoke to Dieter Hauwaerts, VP Operations, Celyadand other industry experts about the top challenges in the Manufacturing Commercialised Cell & Gene Therapies sector.
Download this piece to learn more about:
- Product quality awareness and how functionality tests make manufacturing in a QbD space difficult
- How Downstream processing times that are elongated can have a direct impact on cell quality as the scale is upped
- How stable funding is hard to access with the lengthy R&D timelines and changing regulatory parameters that surround cell and gene therapies
Due to the complex nature of biosimilars, pharma manufacturers need to rely, partly or to a large extent, on external capacities and expertise. The more classically generic the company’s background, the more this holds true. In this issue of Pharmatching Portrays, we showcase some of the Specialist Providers that have stepped in to meet this demand.
Pharma IQ spoke to Dr. Gabriele Dallmann, CEO of Pharmatching.com about biosimilar and the guidelines, players and providers in the sector.
Download this piece to learn more about:
- The challenges of biosimilar monoclonal antibodies
- The players and their responsibilities within the sector
- Regulatory guidance at a glance
In response to the recent bioboom, physicians may consider switching patients to a biosimilar for a more affordable alternative. However, this is a decision that shouldn’t be made in haste and has a few crucial points to be considered.
Pharma IQ spoke to The European Trade Association for biopharmaceutical companies (EBE), European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Download this piece to learn more about the guidance they provided on the key aspects that should frame the decision making process when contemplating a switch to biosimilars.
Speaker Spotlight- Michael Muenzberg, MD, on the good, the bad and the ugly of the biosimilars market
Pharma IQ caught up with summit chair, Dr Michael Muenzberg, MD, to discuss past successes, current challenges and future opportunities in the biosimilars market.